2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science CEO Pleasantly Surprised That Over 1,000 Investors in the First 48 Hours Have Registered Successfully for the Gift Shares; Nevada Property Forges Forward With Updated Renderings and Land Parcel Schematics

Cannabis Science CEO Pleasantly Surprised That Over 1,000 Investors in the First 48 Hours Have Registered Successfully for the Gift Shares; Nevada Property Forges Forward With Updated Renderings and Land Parcel Schematics

COLORADO SPRINGS, CO--(Marketwired - Apr 14, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is very pleased to report CEO Raymond C. Dabney has received an overwhelmingly successful response with over 1,000 shareholders in less than 48 hours successfully registering for the personal stock gift.

Additionally, the company has received more detailed 3D renderings for its 360,000 sq. ft. Nevada drug development facilities and educational complex. The detailed renderings are expected to be completed and publically available next week. The advanced plans will include the zoned property maps, building renderings, University announcement, land parcel schematics for zoning and build-out models.

"We have signed the largest land deal yet with over 360,000 sq. ft. of cultivation and University build-out space for classroom training, medical clinic, and formulations laboratory in Nevada with a confirmed additional 900,000 sq. ft., for possible general public participation. This provides an outstanding platform for our drug development programs and plenty of room for private and public investment opportunities. To date there are a number of diverse interested parties, even including some shareholders. Once the renders and property map are released we will begin to seriously confirm investment opportunities, partnerships, and procurement options for the public," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder.

"This is very special what's happening right now; needless to say our new phone lines have been ringing off the hook. The gift idea was certainly a homerun all around. I have been looking for 'a way to round up our troops'; well we certainly did that, and I have to say the response we got was nothing less then spectacular, the moral support, the investment support, the words of encouragement have all been overwhelming for us all based on an unassuming gift, this is beautiful. We are counting the numbers and I am reading the emails -- it clearly paints the picture of loyalty and true strength. I can announce the next steps after we assess the numbers and best mechanism to deliver the gifts. Please continue to sign up. Teresa and Mitzi have been outstanding, walking everyone through the process that needs any help. Certainly give us a call if you have any issues; we will come up with a plan to receive your information," concludes Mr. Dabney.

More than 1,200 shareholders have uploaded documentation and submitted their information to prove ownership since the information capture page was put up on the Cannabis Science website; https://cannabisscience.com/index.php/loyalty-gift-form on April 11th. The website is continuing to take registrations for the personal share gift from Mr. Dabney.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.